Aptose Biosciences Inc. 8-K

What Happened
Aptose Biosciences, Inc. (APTOF) announced on May 13, 2026 that it issued a press release reporting its results of operations and financial condition and filed an 8-K (Item 2.02) to disclose that press release. The press release is attached to the 8-K as Exhibit 99.1.

Key Details

• Filing date: May 13, 2026 (Form 8-K, Item 2.02).
• Exhibit included: Press Release dated May 13, 2026 (Exhibit 99.1).
• Legal note: Under Form 8-K General Instruction B.2, the press release is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless explicitly stated.
• Technical exhibit: The submission also references the Cover Page Interactive Data File (Inline XBRL).

Why It Matters
This 8-K indicates Aptose has released updated quarterly or period financial information to the market; investors should read the attached press release for the specific earnings, revenue, or operational details. Because the release is furnished (not "filed"), it carries the different legal treatment described above—useful to know when considering incorporation into future SEC filings. Check the press release and subsequent periodic reports (e.g., 10-Q/10-K) for the complete financials and management commentary.